Criticisms of drugs in early development for the treatment of depression: what can be improved?

Bibliography

• Kulkarni SK, Dhir A. Current investigational drugs for major depression. Expert Opin Investig Drugs 2009;18:767–88
   PubMed Web of Science ®Google Scholar
• Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014;75:e441–9
   PubMed Web of Science ®Google Scholar
• Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112–20
   PubMed Web of Science ®Google Scholar
• OF OL, Dinan TG, Cryan JF. Faster, better, stronger: Towards new antidepressant therapeutic strategies. Eur J Pharmacol 2014; Epub ahead of print
   Web of Science ®Google Scholar
• Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 2005;510:49–57
   PubMed Web of Science ®Google Scholar
• Dubovsky SL. Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder. Expert Opin Drug Metab Toxicol 2014;10(5):759–66
   PubMed Web of Science ®Google Scholar
• Khan A, Sambunaris A, Edwards J, et al. Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression. Int Clin Psychopharmacol 2014;29:86–92
   PubMed Web of Science ®Google Scholar
• Wang SM, Han C, Lee SJ, et al. A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract 2013;17:160–9
   PubMed Web of Science ®Google Scholar
• Pae CU, Wang SM, Han C, et al. Vortioxetine: a meta-analysis of 12 short-term, randomised, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci 2014;39(6):140120
   Google Scholar
• Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2014;68:60–82
   PubMed Web of Science ®Google Scholar
• Theunissen EL, Street D, Hojer AM, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther 2013;93:493–501
   PubMed Web of Science ®Google Scholar
• Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012;27:215–23
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17(10):1557–67
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar A, Zajecka J, Jacobson W, et al. Efficacy of vortioxetine on cognitive function in adult patients with major depressive disorder: results of a randomized, double blind, active referenced, placebo-controlled trial [Poster LP-02]. Presented at the 29th World Congress of the International College of Neuropsychopharmacology; Vaccouver, Canada; 2014
   Google Scholar
• Tritschler L, Felice D, Colle R, et al. Vortioxetine for the treatment of major depressive disorder. Expert Rev Clin Pharmacol 2014;7:731–45
   PubMed Web of Science ®Google Scholar
• Zohar J, Nutt DJ, Kupfer DJ, et al. A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol 2014;24:1005–14
   PubMed Web of Science ®Google Scholar
• Pangallo B, Dellva MA, D’Souza DN, et al. A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. J Psychiatr Res 2011;45:748–55
   PubMed Web of Science ®Google Scholar
• Dube S, Dellva MA, Jones M, et al. A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. J Psychiatr Res 2010;44:356–63
   PubMed Web of Science ®Google Scholar
• Ball S, Dellva MA, D’Souza DN, et al. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment. J Affect Disord 2014;167:215–23
   PubMed Web of Science ®Google Scholar
• Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. Psychiatry Investig 2008;5:142–7
   PubMed Web of Science ®Google Scholar
• Shao L, Li W, Xie Q, Yin H. Triple reuptake inhibitors: a patent review (2006 - 2012). Expert Opin Ther Pat 2014;24:131–54
   PubMed Web of Science ®Google Scholar
• Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry 2004;65(Suppl 4):5–10
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011;168:689–701
   PubMed Web of Science ®Google Scholar
• Leuchter AF, Lesser IM, Trivedi MH, et al. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. J Psychiatr Pract 2008;14:271–80
   PubMed Web of Science ®Google Scholar
• Stewart JW, McGrath PJ, Deliyannides RA, Quitkin FM. Does dual antidepressant therapy as initial treatment hasten and increase remission from depression? J Psychiatr Pract 2009;15:337–45
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002;51:183–8
   PubMed Web of Science ®Google Scholar
• Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004;55:296–300
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Worthington JJIII, Iosifescu DV, et al. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety 2006;23:178–81
   PubMed Web of Science ®Google Scholar
• Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010;167:281–8
   PubMed Web of Science ®Google Scholar
• Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009;19:457–65
   PubMed Web of Science ®Google Scholar
• Wong EH, Nikam SS, Shahid M. Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr Opin Investig Drugs 2008;9:28–36
   PubMed Web of Science ®Google Scholar
• Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: the next generation of antidepressants. Curr Neuropharmacol 2008;6:338–43
   PubMed Web of Science ®Google Scholar
• Blier P. The well of novel antidepressants: running dry. J Psychiatry Neurosci 2010;35:219–20
   PubMed Web of Science ®Google Scholar
• Pae CU, Han C, Jun TY. Do we need more than one antidepressant for patients with major depressive disorder? Expert Rev Neurother 2011;11:1561–4
   PubMed Web of Science ®Google Scholar
• Mi MY, Betensky RA. An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials. Clin Trials 2013;10:207–15
   PubMed Web of Science ®Google Scholar
• Yang H, Cusin C, Fava M. Is there a placebo problem in antidepressant trials? Curr Top Med Chem 2005;5:1077–86
   PubMed Web of Science ®Google Scholar
• Marks DM, J T, Pae CU. Innovations in clinical research design and conduct in psychiatry: shifting to pragmatic approaches. Psychiatry Investig 2009;6:1–6
   PubMed Web of Science ®Google Scholar
• Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Moller HJ. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 2011;14:405–12
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Veroniki AA, Siamouli M, Moller HJ. No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis. Ann Gen Psychiatry 2013;12:26
   PubMed Web of Science ®Google Scholar
• Maes M, Fisar Z, Medina M, et al. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates–Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012;20:127–50
   PubMedGoogle Scholar
• Lee SY, Lee SJ, Han C, et al. Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2013;46:224–35
   PubMed Web of Science ®Google Scholar
• Pochwat B, Palucha-Poniewiera A, Szewczyk B, et al. NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opin Investig Drugs 2014;23:1181–92
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351–4
   PubMed Web of Science ®Google Scholar
• Zarate CAJr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856–64
   PubMed Web of Science ®Google Scholar
• DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010;71:1605–11
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67:793–802
   PubMed Web of Science ®Google Scholar
• Hasselmann H. Scopolamine and depression: a role for muscarinic antagonism? CNS Neurol Disord Drug Targets 2014;13:673–83
   PubMed Web of Science ®Google Scholar
• Musazzi L, Milanese M, Farisello P, et al. Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS One 2010;5:e8566
   PubMed Web of Science ®Google Scholar
• Kumamaru E, Numakawa T, Adachi N, et al. Glucocorticoid prevents brain-derived neurotrophic factor-mediated maturation of synaptic function in developing hippocampal neurons through reduction in the activity of mitogen-activated protein kinase. Mol Endocrinol 2008;22:546–58
   PubMed Web of Science ®Google Scholar
• Caddy C, Giaroli G, White TP, et al. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol 2014;4:75–99
   PubMedGoogle Scholar
• Han C, Pae C-U. Oral scopolamine augmentation for major depression. Expert Rev Neurother 2013;13:19–21
   PubMed Web of Science ®Google Scholar
• Jaffe RJ, Novakovic V, Peselow ED. Scopolamine as an antidepressant: a systematic review. Clin Neuropharmacol 2013;36:24–6
   PubMed Web of Science ®Google Scholar
• Wang SM, Han C, Lee SJ, et al. A review of current evidence for acetyl-l-carnitine in the treatment of depression. J Psychiatr Res 2014;53:30–7
   PubMed Web of Science ®Google Scholar
• Duman RS. Neurobiological advances identify novel antidepressant targets. World Psychiatry 2013;12:207–9
   PubMed Web of Science ®Google Scholar
• Altamura AC, Buoli M, Pozzoli S. Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia. Psychiatry Clin Neurosci 2014;68:21–36
   PubMed Web of Science ®Google Scholar
• Mnie-Filali O, Faure C, Lambas-Senas L, et al. Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011;36:1275–88
   PubMed Web of Science ®Google Scholar
• Nandam LS, Jhaveri D, Bartlett P. 5-HT7, neurogenesis and antidepressants: a promising therapeutic axis for treating depression. Clin Exp Pharmacol Physiol 2007;34:546–51
   PubMed Web of Science ®Google Scholar
• O’Leary OF, Dinan TG, Cryan JF. Faster, better, stronger: towards new antidepressant therapeutic strategies. Eur J Pharmacol 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry 2013;45:54–63
   PubMed Web of Science ®Google Scholar
• Blier P. Neurotransmitter targeting in the treatment of depression. J Clin Psychiatry 2013;74(Suppl 2):19–24
   PubMed Web of Science ®Google Scholar
• Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 2011;25:109–27
   PubMed Web of Science ®Google Scholar
• Weisler R, McIntyre RS. The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder. Expert Rev Neurother 2013;13:1161–82
   PubMed Web of Science ®Google Scholar
• Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008;33:88–109
   PubMed Web of Science ®Google Scholar
• Lopez JP, Lim R, Cruceanu C, et al. miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment. Nat Med 2014;20:764–8
   PubMed Web of Science ®Google Scholar